Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 10:39 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1873–1896 of 33,180 matching trials from the live ClinicalTrials.gov search.
Conditions
Patients With Chronic Stroke
Interventions
SSRI, Placebo
Drug
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Breast Cancer, Fatigue
Interventions
CoQ10 & Vitamin E, Placebo & Vitamin E
Dietary Supplement
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
31
States / cities
Phoenix, Arizona • Santa Rosa, California • Newark, Delaware + 24 more
Not listed Not applicable Interventional

Probiotics Pilot Project

NCT04247854
Conditions
Staphylococcus Aureus
Interventions
Bacillus subtilis probiotic, Placebo
Dietary Supplement · Other
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Not applicable Interventional Accepts healthy volunteers

Probiotics, Immunity, Stress, and QofL

NCT05063305
Conditions
Stress, Quality of Life
Interventions
Probiotic, Placebo
Dietary Supplement
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Loma Linda, California
Completed Phase 2 Interventional Results available

Rituximab in New Onset Type 1 Diabetes

NCT00279305
Conditions
Type 1 Diabetes Mellitus
Interventions
Anti-CD20 (rituximab), Placebo Comparator
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years to 45 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 10 more
Completed Phase 4 Interventional Results available

Preventing Osteoporosis Using Denosumab

NCT02753283
Conditions
Osteoporosis, Postmenopausal, Osteoporosis, Osteoporotic Fractures
Interventions
denosumab, Placebo, Calcium and Vitamin D
Drug · Dietary Supplement
Lead sponsor
Susan L. Greenspan
Other
Eligibility
65 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy
Interventions
Aficamten, Placebo
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
12 Years to 17 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
24
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 20 more
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Cognitive Remediation With D-Cycloserine

NCT01399866
Conditions
Smoking Cessation
Interventions
D-cycloserine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Epilepsy, Epilepsy in Children, Epilepsy; Seizure, Disease, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Epileptic Syndromes
Interventions
XEN496
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
1 Month to 6 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Tacoma, Washington
Completed Phase 1 Interventional Accepts healthy volunteers

Functionality of Male Condoms With a Silicone Elastomer Vaginal RIng

NCT01755741
Conditions
Human Immunodeficiency Virus
Interventions
Placebo Vaginal Ring, Condom
Combination Product · Device
Lead sponsor
International Partnership for Microbicides, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
2
States / cities
Berkeley, California • Los Angeles, California
Conditions
Lupus Erythematosus, Systemic
Interventions
Litifilimab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
548 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
53
States / cities
Homewood, Alabama • Beverly Hills, California • Los Angeles, California + 46 more
Conditions
Crohn's Disease
Interventions
Fluconazole, Vancomycin, Neomycin, Ciprofloxacin, Polyethylene Glycol 3350, Promethazine, Fluconazole placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Tourette Syndrome
Interventions
TEV-50717, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
6 Years to 16 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
19
States / cities
Gainesville, Florida • Gulf Breeze, Florida • Miami, Florida + 14 more
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia

NCT03034356
Conditions
Schizophrenia
Interventions
Levetiracetam, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Cystic Fibrosis
Interventions
AZLI, Placebo to match AZLI, Tobramycin inhalation solution
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
71
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 62 more
Conditions
Gastric Cancer
Interventions
Bemarituzumab, Placebo, Modified FOLFOX6
Biological · Drug
Lead sponsor
Five Prime Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
29
States / cities
Tucson, Arizona • Greenbrae, California • Sacramento, California + 23 more
Conditions
Exercise-Induced Asthma
Interventions
Oglemilast, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
2
States / cities
Los Angeles, California • North Dartmouth, Massachusetts
Conditions
Systemic Lupus Erythematosus
Interventions
ALPN-101, Placebo
Drug
Lead sponsor
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Industry
Eligibility
18 Years to 70 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
29
States / cities
Anniston, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more
Conditions
Obstructive Sleep Apnea, Hypertension
Interventions
Lorundrostat, Placebo
Drug
Lead sponsor
Mineralys Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
27
States / cities
Tuscaloosa, Alabama • Chandler, Arizona • Little Rock, Arkansas + 24 more
Completed Phase 2 Interventional Results available

A Study of Oxidative Pathways in MS Fatigue

NCT02804594
Conditions
Progressive Multiple Sclerosis, Fatigue
Interventions
N-acetyl cysteine, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Francisco, California
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Senolytic Agent Improve the Benefit of Platelet-Rich Plasma and Losartan

NCT05025956
Conditions
Femoroacetabular Impingement
Interventions
Fisetin, Placebo
Drug
Lead sponsor
Steadman Philippon Research Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Vail, Colorado
Conditions
Type 2 Diabetes Mellitus
Interventions
WB-010, WB-011, Placebo
Other
Lead sponsor
Pendulum Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Torrance, California • Tustin, California • Youngstown, Ohio + 2 more
Conditions
Alzheimer's Disease
Interventions
LY2062430, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years and older
Enrollment
1,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
16
States / cities
Tucson, Arizona • Los Angeles, California • San Diego, California + 13 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety and Tolerability Study of RJX Drug Product in Healthy Participants

NCT03680105
Conditions
Critical Limb Ischemia
Interventions
RJX, Placebo
Drug
Lead sponsor
Reven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Antonio, Texas